List of Norliqva drug patents

Norliqva is owned by Cmp Dev Llc.

Norliqva contains Amlodipine Besylate.

Norliqva has a total of 2 drug patents out of which 0 drug patents have expired.

Norliqva was authorised for market use on 24 February, 2022.

Norliqva is available in solution;oral dosage forms.

Norliqva can be used as norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; norliqva is indicated for the symptomatic treatment of chronic stable angina; norliqva is indicated for the treatment of confirmed or suspected vasospastic angina.

The generics of Norliqva are possible to be released after 24 February, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253474 CMP DEV LLC Pharmaceutical solution of amlodipine
Feb, 2041

(17 years from now)

US11458095 CMP DEV LLC NA
Feb, 2041

(17 years from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Market Authorisation Date: 24 February, 2022

Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; Norliqva is indicated for the symptomatic treatment of chronic stable ...

Dosage: SOLUTION;ORAL

More Information on Dosage

NORLIQVA family patents

4

United States

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic